Small cell variant of chromophobe renal cell carcinoma: Clinicopathologic and molecular-genetic analysis of 10 cases.


Journal

Bosnian journal of basic medical sciences
ISSN: 1840-4812
Titre abrégé: Bosn J Basic Med Sci
Pays: Bosnia and Herzegovina
ID NLM: 101200947

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 11 01 2022
accepted: 31 01 2022
pubmed: 12 3 2022
medline: 24 8 2022
entrez: 11 3 2022
Statut: epublish

Résumé

The morphologic diversity of chromophobe renal cell carcinoma (ChRCC) is well-known. Aside from typical morphology, pigmented adenomatoid, multicystic and papillary patterns have been described. Ten cases of CHRCC composed of small cell population in various percentages were analysed, using morphologic parameters, immunohistochemistry and next-generation sequencing (NGS) testing. Patients were five males and five females, with age ranging from 40 to 78years. The size of tumors ranged from 2.2 cm to 11 cm (mean 5.17 cm). Small cell component comprised 10 to 80% of the tumor volume, while the remaining was formed by cells with classic ChRCC morphology. The immunohistochemical profile of the small cell component was consistent with typical ChRCC immunophenotype, with CD117 and CK7 positivity. Neuroendocrine markers were negative. Mutations of 13 genes were found: DCIER1, FGFR3, JAK3, SUFO, FAM46C, FANCG, MET, PLCG2, APC, POLE, EPICAM, MUTYH and AR. However, only the PLCG2 mutation is considered pathogenic.The small cell variant of ChRCC further highlights and expand upon existing morphologic heterogeneity spectrum. Recognition of small cell variant of CHRCC is not problematic in tumors, where the "classic" CHRCC component is present. However, in limited material (i.e., core biopsy), this may present a diagnostic challenge. Based on the limited follow-up data available, it appears that the small cell tumor component had no impact on prognosis, since there was no aggressive behavior documented.   Awareness of this unusual pattern and applying additional sections to find classic morphology of ChRCC, as well as excluding neuroendocrine nature by immunohistochemistry, may help resolve difficult cases.

Identifiants

pubmed: 35276058
doi: 10.17305/bjbms.2021.6935
pmc: PMC9392979
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

531-539

Références

Histol Histopathol. 2003 Jan;18(1):165-71
pubmed: 12507296
Virchows Arch. 2020 Mar;476(3):409-418
pubmed: 31760491
Hum Pathol. 2011 Nov;42(11):1751-60
pubmed: 21652056
Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207-17
pubmed: 2859694
Virchows Arch. 2016 Dec;469(6):669-678
pubmed: 27631338
Hum Pathol. 1984 Nov;15(11):1054-61
pubmed: 6490001
Virchows Arch. 2013 Oct;463(4):563-73
pubmed: 23913167
Mod Pathol. 2005 Feb;18(2):161-9
pubmed: 15467713
Pathol Int. 2011 Sep;61(9):552-4
pubmed: 21884307
Int J Cancer. 1997 Nov 14;73(4):521-4
pubmed: 9389566
Virchows Arch. 2005 Apr;446(4):383-93
pubmed: 15756595
Med Mol Morphol. 2013 Mar;46(1):49-55
pubmed: 23338778
Ultrastruct Pathol. 2001 Mar-Apr;25(2):153-8
pubmed: 11407529
Ann Diagn Pathol. 2015 Aug;19(4):261-8
pubmed: 26031603
J Kidney Cancer VHL. 2017 Oct 09;4(4):1-12
pubmed: 29090117
Mod Pathol. 2021 Jul;34(7):1392-1424
pubmed: 33664427
Am J Surg Pathol. 2010 Sep;34(9):1233-40
pubmed: 20679882
Virchows Arch. 2006 Mar;448(3):379-80
pubmed: 16292662
Ann Diagn Pathol. 1998 Jun;2(3):149-53
pubmed: 9845733
Cancer Genet Cytogenet. 2005 Nov;163(1):81-5
pubmed: 16271962
Ann Diagn Pathol. 2020 Feb;44:151448
pubmed: 31918172
Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;56(3):185-9
pubmed: 2464871
Histopathology. 2005 Jun;46(6):712-3
pubmed: 15910607
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Int J Surg Pathol. 2001 Jul;9(3):215-22
pubmed: 11584318
Mod Pathol. 2007 Mar;20(3):303-9
pubmed: 17277768
Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45
pubmed: 2565618
Am J Surg Pathol. 1995 Nov;19(11):1245-56
pubmed: 7573686
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
BJU Int. 2009 May;103(10):1381-4
pubmed: 19154497
J Pathol. 1988 Aug;155(4):277-87
pubmed: 2459332

Auteurs

Joanna Rogala (J)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Fumiyoshi Kojima (F)

Department of Human Pathology, Wakayama Medical University, Wakayama, Japan.

Reza Alaghehbandan (R)

Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

Nikola Ptakova (N)

Department of Biology and Medical Genetics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Czech Republic.

Ana Bravc (A)

Department of Pathology, General Hospital, Slovenj Gradec, Slovenia.

Stela Bulimbasic (S)

Department of Pathology, University Hospital Centre Zagreb, Zagreb, Croatia.

Delia Perez Montiel (D)

Department of Pathology, Institute Nacional de Cancerologia, Mexico City, Mexico.

Maryna Slisarenko (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Leila Ali (L)

Department of Pathology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.

Levente Kuthi (L)

Department of Pathology, University of Szeged, Szeged, Hungary.

Kristyna Pivovarcikova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Kvetoslava Michalova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Boris Bartovic (B)

Departmnet of Pathology, Cytopathos, Bratislava, Slovakia.

Adriena Bartos Vesela (A)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Olga Dolejsova (O)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Michal Michal (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Ondrej Hes (O)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH